PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.68%
Cash & equivalents yoy growth below half of CRVO's 151.87%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
13.68%
Below half of CRVO's 151.87%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.59%
Below half of CRVO's 151.98%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-11.93%
0.5-0.75x CRVO's -17.93%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-88.66%
Above 1.5x CRVO's -1.21%. Michael Burry warns of potential hidden liabilities or intangible bloat.
-8.29%
≥ 1.5x CRVO's -0.60%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Below half of CRVO's 102.72%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-14.12%
Less than half of CRVO's 74.58%. David Dodd sees a more disciplined AP approach or lower volume.
2.34%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
14.12%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
-2.34%
Less than half of CRVO's -100.00%. David Dodd sees fewer expansions in other current obligations.
-12.65%
Similar yoy to CRVO's -13.25%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-36.66%
Above 1.5x CRVO's -5.60%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-14.12%
1.1-1.25x CRVO's -11.99%. Bill Ackman questions if the firm is incurring more total obligations than competitor.
5.56%
Less than half of CRVO's 59.19%. David Dodd sees fewer share issuances vs. competitor.
-2.30%
0.5-0.75x CRVO's -4.38%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.36%
Below half CRVO's 116.20%. Michael Burry sees potential underperformance in building shareholder capital.
13.10%
Below half CRVO's 102.72%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-14.09%
50-75% of CRVO's -19.48%. Bruce Berkowitz sees relatively smaller yoy debt additions.
-14.00%
Less than half of CRVO's -153.26%. David Dodd sees better deleveraging or stronger cash buildup than competitor.